Fig. 2From: A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapiesClinical trials concerning the CRISPR-Cas9 application in the context of CAR-T cell-based tumor immunotherapy registered in ClinicalTrials.gov (June 2021). The schematic presents conducted or ongoing clinical trials based on the CRISPR-Cas9-mediated genome edition in CAR-T cell depending on the study location (A), study phase (B), study status (C), and target antigen (D) registered in ClinicalTrials.gov (June 2021)Back to article page